Current situation of the supply of oncological drugs in Mexico
In response to the mobilizations organized by oncology patients and their families due to the shortage of essential drugs, President Claudia Sheinbaum reported during her morning conference that the federal government has managed to acquire 96% of the required oncology medications. However, it acknowledged difficulties in the supply of three specific drugs, attributing the problem to limitations in the production chain and not to failures in the bidding processes.
Details on distribution and strategic reserves
Sheinbaum emphasized the existence of a strategic reserve of specialized medications, designed to expedite delivery to patients in critical situations. “We have implemented an additional distribution scheme to ensure that supplies reach even the most remote communities,” he declared. This system, currently in the implementation phase, seeks to correct geographic disparities in access to treatments.
According to data provided by the administration, the centralized purchasing scheme has allowed resources to be optimized, although bottlenecks persist in highly specialized drugs. The president stressed that transparency in management has been a priority: “Since the beginning of this administration, we have reported progress and challenges clearly.”
Analysis of pending challenges
Despite progress, the lack of three key medications reveals structural vulnerabilities. Experts in pharmaceutical logistics point out that these cases could be related to dependence on single suppliers or international regulations. A 2024 report from the Pan American Health Organization (PAHO) warned of risks in global supply chains for cancer therapies, especially in countries with fragmented health systems.
The creation of a permanent supply team, mentioned by Sheinbaum, responds to this problem. However, civil organizations such as Con Ganas de Vivir demand specific deadlines to normalize supply and independent audits to validate the official figures.
Impact on patients and next steps
While the government ensures that 96% of purchases cover primary demand, affected families report interruptions in treatments. Data from public hospitals show that 78% of complaints about shortages correspond to the three drugs not purchased, all of them used in hematological and metastatic cancers.
The new distribution model, which will include traceability technology, aims to reduce these cases. “We are prioritizing municipalities with less medical coverage,” explained an official from the Ministry of Health on condition of anonymity.
Are you interested in learning more about public health policies? Share this analysis on your social networks and follow our coverage on strategies to strengthen the national medical system. #HealthForAll




